Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:1755-1760
Published online before print August 19, 2004, doi: 10.1161/01.ATV.0000142804.27420.5b
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
24/10/1755    most recent
01.ATV.0000142804.27420.5bv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brewer, H. B.
Right arrow Articles by Joyce, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brewer, H. B., Jr
Right arrow Articles by Joyce, C.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:1755.)
© 2004 American Heart Association, Inc.


Brief Reviews

Regulation of Plasma High-Density Lipoprotein Levels by the ABCA1 Transporter and the Emerging Role of High-Density Lipoprotein in the Treatment of Cardiovascular Disease

H. Bryan Brewer, Jr; Alan T. Remaley; Edward B. Neufeld; Federica Basso; Charles Joyce

From the Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md.

Correspondence to H. Bryan Brewer, Jr, Molecular Disease Branch, NHLBI, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892. E-mail bryan{at}mdb.nhlbi.nih.gov

High-density lipoproteins (HDL) protect against cardiovascular disease. HDL removes and transports excess cholesterol from peripheral cells to the liver for removal from the body. HDL also protects low-density lipoproteins (LDL) from oxidation and inhibits expression of adhesion molecules in endothelial cells, preventing monocyte movement into the vessel wall. The ABCA1 transporter regulates intracellular cholesterol levels in the liver and in peripheral cells by effluxing excess cholesterol to lipid-poor apoA-I to form nascent HDL, which is converted to mature {alpha}-HDL by esterification of cholesterol to cholesteryl esters (CE) by lecithin cholesterol acyltransferase. The hepatic ABCA1 transporter and apoA-I are major determinants of levels of plasma {alpha}-HDL cholesterol as well as poorly lipidated apoA-I, which interact with ABCA1 transporters on peripheral cells in the process of reverse cholesterol transport. Cholesterol in HDL is transported directly back to the liver by HDL or after transfer of CE by the cholesteryl ester transfer protein (CETP) by the apoB lipoproteins. Current approaches to increasing HDL to determine the efficacy of HDL in reducing atherosclerosis involve acute HDL therapy with infusions of apoA-I or apoA-I mimetic peptides and chronic long-term therapy with selective agents to increase HDL, including CETP inhibitors.

High-density lipoproteins (HDL) protect against cardiovascular disease. Current approaches to increasing HDL to determine its efficacy in reducing atherosclerosis involve acute HDL therapy with infusions of apoA-I or apoA-I mimetic peptides and chronic long-term therapy with selective agents to increase HDL, including CETP inhibitors.


Key Words: ABCA1 transporter • cholesterol • cholesteryl ester transfer protein • cholesteryl ester transfer protein inhibitor • apoA-I




This article has been cited by other articles:


Home page
EndocrinologyHome page
I. Tancevski, A. Wehinger, E. Demetz, P. Eller, K. Duwensee, J. Huber, K. Hochegger, W. Schgoer, C. Fievet, F. Stellaard, et al.
Reduced Plasma High-Density Lipoprotein Cholesterol in Hyperthyroid Mice Coincides with Decreased Hepatic Adenosine 5'-Triphosphate-Binding Cassette Transporter 1 Expression
Endocrinology, July 1, 2008; 149(7): 3708 - 3712.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. H. Hassan, D. Bailey, D.-Y. D. Lee, I. Iatan, A. Hafiane, I. Ruel, L. Krimbou, and J. Genest
Quantitative Analysis of ABCA1-dependent Compartmentalization and Trafficking of Apolipoprotein A-I: IMPLICATIONS FOR DETERMINING CELLULAR KINETICS OF NASCENT HIGH DENSITY LIPOPROTEIN BIOGENESIS
J. Biol. Chem., April 25, 2008; 283(17): 11164 - 11175.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. R. Superko and S. King III
Lipid Management to Reduce Cardiovascular Risk: A New Strategy Is Required
Circulation, January 29, 2008; 117(4): 560 - 568.
[Full Text] [PDF]


Home page
J. Lipid Res.Home page
H. H. Hassan, M. Denis, D.-Y. D. Lee, I. Iatan, D. Nyholt, I. Ruel, L. Krimbou, and J. Genest
Identification of an ABCA1-dependent phospholipid-rich plasma membrane apolipoprotein A-I binding site for nascent HDL formation: implications for current models of HDL biogenesis
J. Lipid Res., November 1, 2007; 48(11): 2428 - 2442.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Vedhachalam, P. T. Duong, M. Nickel, D. Nguyen, P. Dhanasekaran, H. Saito, G. H. Rothblat, S. Lund-Katz, and M. C. Phillips
Mechanism of ATP-binding Cassette Transporter A1-mediated Cellular Lipid Efflux to Apolipoprotein A-I and Formation of High Density Lipoprotein Particles
J. Biol. Chem., August 24, 2007; 282(34): 25123 - 25130.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
A. Soro-Paavonen, J. Naukkarinen, M. Lee-Rueckert, H. Watanabe, E. Rantala, S. Soderlund, A. Hiukka, P. T. Kovanen, M. Jauhiainen, L. Peltonen, et al.
Common ABCA1 variants, HDL levels, and cellular cholesterol efflux in subjects with familial low HDL
J. Lipid Res., June 1, 2007; 48(6): 1409 - 1416.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
L. Sarov-Blat, R. S. Kiss, B. Haidar, N. Kavaslar, M. Jaye, M. Bertiaux, K. Steplewski, M. R. Hurle, D. Sprecher, R. McPherson, et al.
Predominance of a Proinflammatory Phenotype in Monocyte-Derived Macrophages From Subjects With Low Plasma HDL-Cholesterol
Arterioscler. Thromb. Vasc. Biol., May 1, 2007; 27(5): 1115 - 1122.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
S. Kurumada, A. Onishi, H. Imai, K. Ishii, T. Kobayashi, and S. B. Sato
Stage-Specific Association of Apolipoprotein A-I and E in Developing Mouse Retina
Invest. Ophthalmol. Vis. Sci., April 1, 2007; 48(4): 1815 - 1823.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
M. Fukuda, M. Nakano, S. Sriwongsitanont, M. Ueno, Y. Kuroda, and T. Handa
Spontaneous reconstitution of discoidal HDL from sphingomyelin-containing model membranes by apolipoprotein A-I
J. Lipid Res., April 1, 2007; 48(4): 882 - 889.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. Wehinger, I. Tancevski, W. Schgoer, P. Eller, K. Hochegger, M. Morak, A. Hermetter, A. Ritsch, J. R. Patsch, and B. Foeger
Phospholipid Transfer Protein Augments Apoptosis in THP-1-Derived Macrophages Induced by Lipolyzed Hypertriglyceridemic Plasma
Arterioscler. Thromb. Vasc. Biol., April 1, 2007; 27(4): 908 - 915.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
M. Lee-Rueckert, R. Vikstedt, J. Metso, C. Ehnholm, P. T. Kovanen, and M. Jauhiainen
Absence of endogenous phospholipid transfer protein impairs ABCA1-dependent efflux of cholesterol from macrophage foam cells
J. Lipid Res., August 1, 2006; 47(8): 1725 - 1732.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
P. T. Duong, H. L. Collins, M. Nickel, S. Lund-Katz, G. H. Rothblat, and M. C. Phillips
Characterization of nascent HDL particles and microparticles formed by ABCA1-mediated efflux of cellular lipids to apoA-I
J. Lipid Res., April 1, 2006; 47(4): 832 - 843.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. D. Otvos, D. Collins, D. S. Freedman, I. Shalaurova, E. J. Schaefer, J. R. McNamara, H. E. Bloomfield, and S. J. Robins
Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial
Circulation, March 28, 2006; 113(12): 1556 - 1563.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
K. M. Thelen, K. M. Rentsch, U. Gutteck, M. Heverin, M. Olin, U. Andersson, A. von Eckardstein, I. Bjorkhem, and D. Lutjohann
Brain Cholesterol Synthesis in Mice Is Affected by High Dose of Simvastatin but Not of Pravastatin
J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1146 - 1152.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. Duffy and D. J. Rader
Emerging Therapies Targeting High-Density Lipoprotein Metabolism and Reverse Cholesterol Transport
Circulation, February 28, 2006; 113(8): 1140 - 1150.
[Full Text] [PDF]


Home page
J. Lipid Res.Home page
A. Nilsson and R.-D. Duan
Absorption and lipoprotein transport of sphingomyelin
J. Lipid Res., January 1, 2006; 47(1): 154 - 171.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Koldamova, M. Staufenbiel, and I. Lefterov
Lack of ABCA1 Considerably Decreases Brain ApoE Level and Increases Amyloid Deposition in APP23 Mice
J. Biol. Chem., December 30, 2005; 280(52): 43224 - 43235.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
Z. T. Bloomgarden
2nd International Symposium on Triglycerides and HDL: Metabolic syndrome
Diabetes Care, October 1, 2005; 28(10): 2577 - 2584.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Navab, G.M. Anantharamaiah, S. T. Reddy, S. Hama, G. Hough, V. R. Grijalva, N. Yu, B. J. Ansell, G. Datta, D. W. Garber, et al.
Apolipoprotein A-I Mimetic Peptides
Arterioscler. Thromb. Vasc. Biol., July 1, 2005; 25(7): 1325 - 1331.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. J. Taylor, L. E. Sullenberger, H. J. Lee, J. K. Lee, and K. A. Grace
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins
Circulation, December 7, 2004; 110(23): 3512 - 3517.
[Abstract] [Full Text] [PDF]